Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease
Status:
Unknown status
Trial end date:
2021-02-16
Target enrollment:
Participant gender:
Summary
Inhibition of acetylcholinesterase has been a effective treatment for Alzheimer's disease.
Octohydroaminoacridine, a new acetylcholinesterase inhibitor, is a potential treatment for
Alzheimer's disease. The investigators conducted a 26 weeks, randomized, double-blind,
double-dummy, placebo- and positive- parallel controlled and extended single arm to 54 weeks
multicentre phase III clinical trial to investigate the effects of octohydroaminoacridine in
patients with mild-to-moderate Alzheimer's disease. Patients were randomized to receive
placebo thrice daily, or octohydroaminoacridine 4 mg/TID or ARICEPT 5mg/QD.